Oppenheimer started coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Tuesday morning, The Fly reports. The firm issued an outperform rating and a $52.00 target price on the stock. Oppenheimer also issued estimates for Apellis Pharmaceuticals’ Q2 2019 earnings at ($0.80) EPS, Q3 2019 earnings at ($0.84) EPS, Q4 2019 earnings at ($0.84) EPS, FY2019 earnings at ($3.34) EPS, Q1 2020 earnings at ($0.82) EPS, Q2 2020 earnings at ($0.82) EPS, Q3 2020 earnings at ($0.84) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.30) EPS, FY2021 earnings at ($3.01) EPS, FY2022 earnings at ($0.94) EPS and FY2023 earnings at $9.19 EPS.
Several other analysts have also issued reports on the stock. Robert W. Baird started coverage on shares of Uniqure in a research report on Thursday, March 28th. They issued an outperform rating and a $85.00 price target on the stock. Cantor Fitzgerald restated a buy rating and issued a $107.00 price target on shares of Perrigo in a research report on Wednesday, May 8th. Zacks Investment Research upgraded shares of HANNOVER RUECK/S from a sell rating to a hold rating in a research report on Friday, May 17th. ValuEngine upgraded shares of Vistra Energy from a hold rating to a buy rating in a research report on Wednesday, July 3rd. Finally, Cowen restated a hold rating on shares of Sunesis Pharmaceuticals in a research report on Sunday, June 16th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $45.43.
Shares of APLS opened at $27.35 on Tuesday. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $22.89. Apellis Pharmaceuticals has a one year low of $11.45 and a one year high of $29.07.
Several institutional investors have recently modified their holdings of APLS. Hillhouse Capital Advisors Ltd. acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $29,410,000. BlackRock Inc. boosted its position in shares of Apellis Pharmaceuticals by 30.8% during the 4th quarter. BlackRock Inc. now owns 3,730,626 shares of the company’s stock valued at $49,208,000 after acquiring an additional 877,431 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $4,313,000. Assenagon Asset Management S.A. acquired a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $6,025,000. Finally, Victory Capital Management Inc. boosted its position in shares of Apellis Pharmaceuticals by 21.7% during the 1st quarter. Victory Capital Management Inc. now owns 1,688,663 shares of the company’s stock valued at $32,929,000 after acquiring an additional 300,900 shares in the last quarter. Institutional investors and hedge funds own 63.45% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.